Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 6/20 | 0.35 |
| ▸ | DRD2 | P14416 | 4/20 | 0.35 |
| ▸ | DRD4 | P21917 | 4/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7433439 | 0.86 | PRCP (0.49) | MAPTTSHR | |
| SCHEMBL17760557 | 0.72 | ADRA2A (0.45) | ADRA2AMAPK1ALDH1A1CYP2D6ALOX15 | |
| SCHEMBL5266413 | 0.72 | PTPRA (0.39) | DRD1DRD2DRD4ADRA2AADRA2B | |
| SCHEMBL1471223 | 0.71 | DRD1 (0.37) | DRD1DRD2DRD4ADRA2AADRA2B | |
| SCHEMBL6659680 | 0.68 | TRPM5 (0.41) | DRD1DRD2DRD4ADRA2AADRA2B | |
| SCHEMBL3172947 | 0.68 | ESR1 (0.34) | — | |
| SCHEMBL11120312 | 0.67 | CREBBP (0.34) | HSD17B10KDM4EHPGDTSHR | |
| SCHEMBL27741885 | 0.66 | DRD1 (0.38) | DRD1DRD2DRD4ADRA2AADRA2B | |
| SCHEMBL23356541 | 0.66 | RECQL (0.35) | DRD1DRD2DRD4ADRA2AADRA2B | |
| SCHEMBL14494409 | 0.66 | RAB9A (0.42) | ALDH1A1MAPTTP53CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190054071-A1 | SMALL MOLECULE INHIBITORS OF PENDRIN ION EXCHANGE AND PHARMACEUTICAL COMPOSITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-02-21 | — | — | US | disclosed |
| EP-3150600-B1 | DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR | QILU PHARMACEUTICAL CO LTD (CN) | 2018-06-27 | — | — | EP | disclosed |
| US-9938301-B2 | Dihydropyrimido fused ring derivative as HBV inhibitor | QILU PHARMACEUTICAL CO., LTD. (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170197986-A1 | DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2017-07-13 | — | — | US | disclosed |
| EP-3150600-A1 | DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR | Medshine Discovery Inc. (CN) | 2017-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190054071-A1 | SMALL MOLECULE INHIBITORS OF PENDRIN ION EXCHANGE AND PHARMACEUTICAL COMPOSITIONS | SLC26A4, CFTR, SLC7A5 | DRD1 2509/4885DRD2 2286/4885DRD4 3069/4885 |
| US-20170197986-A1 | DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR | TMBIM6, HAVCR2, HDGF | DRD1 4681/4885DRD2 4810/4885DRD4 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.